Status:

UNKNOWN

Fuzheng Yiliu-1010

Lead Sponsor:

Guangdong Provincial Hospital of Traditional Chinese Medicine

Conditions:

Colorectal Cancer Stage II and III

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

Real world study was used to evaluate the therapeutic effect of Fuzheng anti-tumor therapy on colorectal cancer patients in stage II and III after surgery and standard chemotherapy, and the prediction...

Eligibility Criteria

Inclusion

  • The age of the patients was 18-75 years old;
  • Radical resection of colorectal cancer (negative margin) was performed;
  • Patients with stage II high risk and stage III colorectal cancer confirmed by histology;
  • No liver, peritoneal or distant metastasis was found;
  • Patients with colorectal cancer who received standard chemotherapy or radiotherapy after operation and had no recurrence or metastasis at the end of radiotherapy and chemotherapy;
  • ECoG (Eastern Cooperative Oncology Group) score was 0-1; KPS score was 70 or above;
  • Liver function: SGOT and SGPT were less than 1.5 times of normal value, bilirubin was less than 1.5 mg / dl;
  • Renal function: creatinine \< 1.8mg/dl.

Exclusion

  • Allergic to the drug of this scheme;
  • Pregnant or lactating women with fertility requirements during the study period;
  • Severe hypertension, coronary heart disease, diabetes and so on, which are under control for half a year due to cardiovascular accident and poor drug control, are accompanied with other uncontrollable benign diseases such as lung, kidney, liver, infection, etc;
  • Participate in other studies before and during treatment;
  • There was a history of other malignant tumors or multi-source tumors within one year;
  • Chronic hepatitis B or C (high copy viral DNA) or activity in HIV infection history or active phase;
  • Patients with tuberculosis or seizures who need to be treated (e.g. steroids or antiepileptic therapy).

Key Trial Info

Start Date :

June 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

189 Patients enrolled

Trial Details

Trial ID

NCT04459754

Start Date

June 29 2020

End Date

December 31 2024

Last Update

July 7 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Guangdong Provincial Hospital of Chinese Medicine

Guangzhou, Guangdong, China, 510000

Fuzheng Yiliu-1010 | DecenTrialz